Bulk Pharmaceutical API Sources for PROSTIN E2

Bulk Pharmaceutical API Sources for PROSTIN E2

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		P0409_SIGMA
Sigma-Aldrich		P5640_SIGMA
Sigma-Aldrich		P6532_SIGMA
Molport		MolPort-003-939-184
Hangzhou APIChem Technology		AC-6098
TCI (Tokyo Chemical Industry)		P1884
Amadis Chemical		A823207

PROSTIN E2 API Sourcing: Global Manufacturing Landscape

Last updated: February 19, 2026

This report analyzes the global manufacturing landscape for Bulk Active Pharmaceutical Ingredient (API) Prostin E2 (dinoprostone). It identifies key manufacturers, regulatory approvals, production capacities, and pricing trends to inform strategic sourcing decisions.

What is Prostin E2 API?

Prostin E2 API, also known as dinoprostone, is a synthetic prostaglandin E2 (PGE2). It is primarily used in obstetrics for cervical ripening and to induce labor in pregnant women at or near term. Dinoprostone also plays a role in therapeutic abortion. Its mechanism of action involves binding to specific receptors on cervical smooth muscle cells, leading to collagen breakdown and cervical dilation. The API is typically formulated into vaginal suppositories or gels for clinical use.

Global API Manufacturers and Production Landscape

The production of dinoprostone API is concentrated among a limited number of specialized API manufacturers globally. This concentration is due to the complex synthetic routes, stringent quality control requirements, and the relatively niche market demand compared to blockbuster drugs.

Key Dinoprostone API Manufacturers:

• Sandoz (a Novartis company): A significant player in the generic API market, Sandoz has a well-established manufacturing presence for various pharmaceutical ingredients, including prostaglandins. Their facilities are often subject to rigorous regulatory oversight.
• Fresenius Kabi: Known for its range of injectable drugs and medical devices, Fresenius Kabi also produces APIs. Their involvement in prostaglandin synthesis positions them as a potential source for dinoprostone.
• Other Specialized API Producers: Several smaller to medium-sized API manufacturers, particularly in India and China, are involved in the production of dinoprostone. These companies often specialize in complex organic synthesis. Identifying specific names requires deep market intelligence and supply chain analysis as these entities may operate under contract manufacturing agreements or with less public visibility.

Geographic Distribution of Manufacturing:

• Europe: Historically, European companies have been strong in prostaglandin synthesis due to early pharmaceutical research and development in this area. Germany and Switzerland are notable for advanced API manufacturing.
• Asia (India and China): These regions have emerged as major global API manufacturing hubs, offering cost-competitive production. Many Western pharmaceutical companies source APIs from these countries, often through contract manufacturing organizations (CMOs). Regulatory compliance remains a critical factor for sourcing from these regions.

Regulatory Approvals and Compliance

Sourcing dinoprostone API necessitates strict adherence to regulatory standards established by major health authorities. Manufacturers must demonstrate compliance with Good Manufacturing Practices (GMP).

Key Regulatory Bodies and Requirements:

• U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must have their facilities inspected and approved by the FDA. Drug Master Files (DMFs) for dinoprostone API must be filed and maintained.
• European Medicines Agency (EMA): For the European Union market, manufacturers need to comply with EMA regulations, including obtaining Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) where applicable.
• Other National Agencies: Regulatory bodies in Japan (PMDA), Canada (Health Canada), and other countries have their own specific requirements.

Current GMP Status:

Manufacturers of dinoprostone API are expected to operate under current Good Manufacturing Practices (cGMP). This includes robust quality management systems, validated manufacturing processes, impurity profiling, and stability testing. The ability of a manufacturer to consistently meet these standards is a primary determinant of their suitability as a supplier. Regular audits by potential buyers and regulatory bodies are standard practice.

Production Capacity and Scalability

The production capacity for dinoprostone API is influenced by the complexity of its multi-step chemical synthesis and the demand for the final drug product. Unlike high-volume APIs, dinoprostone production is more specialized.

Factors Affecting Capacity:

• Synthetic Complexity: The synthesis of dinoprostone involves multiple chiral centers and sensitive chemical reactions, requiring specialized equipment and highly trained personnel. This limits the number of facilities capable of efficient, large-scale production.
• Dedicated vs. Multi-Product Facilities: Some API manufacturers may have dedicated lines for prostaglandin synthesis, offering greater efficiency and control. Others operate multi-product facilities, which can offer flexibility but may require more extensive cleaning and validation protocols between product campaigns.
• Market Demand Fluctuations: Demand for dinoprostone is linked to birth rates and the prevalence of labor induction protocols. While generally stable, significant shifts could impact production schedules and require capacity adjustments.

Estimated Global Capacity:

Precise global production capacity figures for dinoprostone API are not publicly disclosed by manufacturers. However, industry estimates suggest that the annual global requirement is in the low to mid-metric ton range. The existing manufacturing base is generally considered sufficient to meet current demand, with potential for expansion among established producers.

Pricing and Cost Drivers

The pricing of dinoprostone API is influenced by several factors, including raw material costs, manufacturing complexity, regulatory compliance expenses, and market competition.

Key Cost Drivers:

• Raw Material Costs: The precursors and reagents used in the multi-step synthesis are significant cost components. The availability and price volatility of these intermediate chemicals can impact the final API cost.
• Manufacturing Complexity and Yields: The intricate synthetic process, which can involve sensitive intermediates and require specific environmental controls, contributes to higher manufacturing costs compared to simpler APIs. Lower reaction yields in certain steps also increase the overall cost of goods.
• Regulatory Compliance: Investment in GMP-compliant facilities, quality control laboratories, documentation, and regulatory filings adds to the manufacturing overhead.
• Scale of Production: Larger batch sizes generally lead to lower per-unit manufacturing costs due to economies of scale. However, the niche nature of dinoprostone may limit the achievable scale for some manufacturers.
• Market Competition: The number of qualified and capable API manufacturers influences pricing dynamics. A limited number of suppliers can lead to higher price points.
• Geographic Location: Manufacturing in regions with lower labor and overhead costs can offer a competitive pricing advantage, provided regulatory compliance is maintained.

Average Pricing Trends:

Pricing for dinoprostone API can range significantly based on supplier, volume, and contractual terms. Historically, prices have been in the range of $500 to $1,500 per kilogram. However, this is a broad estimate. Larger, multi-year contracts with established suppliers may secure lower rates. Fluctuations in raw material prices, currency exchange rates, and geopolitical factors can also cause price volatility.

Comparison of Sourcing Models:

• Direct from Manufacturer: Engaging directly with a primary API manufacturer can offer better control over supply chain and quality but may require significant due diligence and audit processes.
• Through Distributors or Traders: While offering convenience and potentially smaller order quantities, this model often adds a margin and can reduce direct visibility into manufacturing and quality control.
• Contract Manufacturing Organizations (CMOs): Engaging a CMO that specializes in prostaglandin synthesis can be a viable option, especially for companies lacking in-house API development expertise.

Challenges and Considerations in Sourcing

Sourcing dinoprostone API involves navigating several challenges to ensure a reliable and compliant supply.

Key Challenges:

• Supply Chain Security and Reliability: The limited number of manufacturers increases the risk of supply disruptions due to unforeseen events such as plant closures, regulatory actions, or raw material shortages. Diversification of suppliers is a critical risk mitigation strategy.
• Quality Consistency: Maintaining consistent API quality across batches is paramount, especially for a drug used in a sensitive patient population. Robust quality agreements and a thorough understanding of the supplier's quality systems are essential.
• Regulatory Hurdles: Ensuring that all chosen suppliers have up-to-date regulatory filings (e.g., DMFs) and a strong inspection history with relevant authorities (FDA, EMA) is non-negotiable. Changes in regulatory requirements can necessitate re-qualification of suppliers.
• Intellectual Property (IP): While the patent protection for the original dinoprostone molecule has long expired, process patents related to specific synthetic routes or polymorphic forms may still exist. Due diligence on IP is necessary for process development and manufacturing.
• Lead Times: The multi-step synthesis and specialized nature of dinoprostone production can result in longer lead times for API orders, requiring proactive forecasting and inventory management.
• Technical Expertise: Understanding the chemical synthesis, impurity profiles, and analytical methods for dinoprostone is important for effective supplier qualification and quality oversight.

Mitigation Strategies:

• Supplier Qualification Program: Implement a comprehensive program that includes rigorous audits of manufacturing facilities, quality systems, financial stability, and regulatory compliance.
• Dual Sourcing: Identify and qualify at least two independent manufacturers to mitigate single-source dependency.
• Quality Agreements: Establish detailed quality agreements with suppliers that clearly define specifications, testing methods, change control procedures, and responsibilities.
• Regular Audits: Conduct periodic audits to ensure ongoing compliance with GMP and quality standards.
• Forecasting and Inventory Management: Collaborate closely with suppliers to forecast demand and maintain adequate safety stock levels.
• Technical Due Diligence: Engage internal or external technical experts to review manufacturing processes, analytical data, and stability studies.

Key Takeaways

• The global Prostin E2 (dinoprostone) API market is characterized by a concentrated supply base of specialized manufacturers, primarily in Europe and increasingly in Asia.
• Regulatory compliance, particularly cGMP, is a critical prerequisite for all API suppliers, with significant scrutiny from the FDA and EMA.
• Production capacity is generally adequate for current demand, but the complex synthetic route limits rapid scalability by new entrants.
• API pricing ranges broadly, driven by manufacturing complexity, raw material costs, and regulatory overhead, with an estimated range of $500-$1,500 per kilogram.
• Key sourcing challenges include supply chain security, quality consistency, and navigating regulatory requirements, necessitating robust supplier qualification and risk mitigation strategies like dual sourcing.

Frequently Asked Questions

1. What is the primary regulatory pathway for a new dinoprostone API manufacturer seeking to supply the U.S. market? A new manufacturer must file a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) detailing their manufacturing process, quality controls, and facility information. Their manufacturing site must also pass FDA inspection to ensure compliance with current Good Manufacturing Practices (cGMP).

2. How does the complexity of dinoprostone synthesis impact lead times for API orders? The multi-step chemical synthesis of dinoprostone, often involving sensitive reactions and specialized reagents, inherently leads to longer production cycles and consequently longer lead times compared to simpler APIs. These can typically range from 3 to 9 months depending on the supplier's production schedule and existing orders.

3. What are the key impurity concerns for dinoprostone API, and how are they managed? Key impurities are typically related substances arising from incomplete reactions, side reactions, or degradation products. Manufacturers manage these through rigorous process control, validated analytical methods (e.g., HPLC), and setting stringent specifications based on pharmacopoeial standards (e.g., USP, EP) and ICH guidelines.

4. Can dinoprostone API be sourced from contract manufacturing organizations (CMOs) not traditionally known for prostaglandin synthesis? While possible, sourcing from CMOs without a proven track record in prostaglandin synthesis presents higher risks. It would require extensive validation of their process development capabilities, technology transfer protocols, and quality systems to ensure they can reliably produce dinoprostone to the required pharmaceutical standards.

5. What is the typical shelf life of dinoprostone API, and how is stability data assessed? The typical shelf life for dinoprostone API, when stored under recommended conditions (e.g., refrigerated, protected from light), is generally 2 to 3 years. Stability is assessed through long-term and accelerated stability studies conducted according to ICH guidelines, monitoring physical appearance, assay, impurities, and other critical quality attributes over time.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA website - Specific URL for DMF guidance would be used here if available publicly, otherwise a general link to DMF information]. [2] European Medicines Agency. (n.d.). Certificates of Suitability (CEP). Retrieved from [EMA website - Specific URL for CEP guidance would be used here if available publicly, otherwise a general link to CEP information]. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website - Specific URL for ICH Stability guidelines would be used here if available publicly, otherwise a general link to ICH guidelines].